Online citations, reference lists, and bibliographies.

Treatment Of Malignant Mesothelioma

Michael T. Jaklitsch, Marcelline Grondin, Mike Sugarbaker
Published 2001 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare tumor that predominantly afflicts men over 50 years of age. Nearly 3000 MPMs are reported annually in the United States with the incidence expected to rise into the new millenium. Over the past 40 years, MPM has been unequivocally linked to asbestos exposure worldwide. Recently, however, a new theory on the carcinogenesis of this tumor has been proposed with the isolation of a simian virus (SV 40)-like gene sequence in mesothelioma tumor cells. The clinical presentation of MPM is variable, although most patients typically present with dyspnea, chest pain, or pleural effusion. Obtaining a diagnosis of MPM has been greatly assisted by video-assisted surgery and the use of immunohistochemistry and electron microscopic techniques, which help distinguish MPM from other tumor pathologies such as adenocarcinoma. Computed tomography and magnetic resonance imaging have been also useful for determining tumor burden and resectability. Traditionally, strategies for the treatment of MPM have included supportive care, surgery, radiotherapy, and chemotherapy. Survival with supportive care alone ranges between 4 and 12 months. Single-modality therapy using traditional approaches (surgery, radiotherapy, chemotherapy) alone has failed to improve patient survival significantly. Recently, results using a multimodality approach have been favorable. In particular, cytoreductive surgery (pleuropneumonectomy) followed by sequential chemotherapy and radiotherapy have demonstrated improved survival, especially for patients with epithelial histology, negative resection margins, and no metastases to extrapleural lymph nodes. Innovative therapies such as the use of photodynamic, targeted cytokines and gene therapy are currently being investigated for management of MPM.



This paper is referenced by
10.5772/55292
Mesothelioma: An Evidence-Based Review
Julie Goudreault (2013)
10.1111/j.1743-7563.2010.01319.x
Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma.
Pinar Hanife Kara (2010)
10.1259/bjr.20170814
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
Hugh St. A. Elliott (2018)
10.1007/s11864-014-0314-4
Local and Systemic Therapies for Malignant Pleural Mesothelioma
Daniel R. Gomez (2014)
Bisphosphonates Inhibit the GrowthofMesothelioma Cells In vitro and In vivo
Savita Wakchoure (2006)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1007/978-1-4471-2942-4_18
Pathology of the Peritoneum
Asma Z Faruqi (2014)
10.1007/978-1-61779-797-2
In Vivo Cellular Imaging Using Fluorescent Proteins
Robert M Hoffman (2012)
Original Article Silencing receptor EphA2 induces apoptosis and attenu- ates tumor growth in malignant mesothelioma
Kamal A. Mohammed (2011)
10.1245/s10434-006-9160-3
Extrapleural Pneumonectomy Is the Preferred Surgical Management in the Multimodality Therapy of Pleural Mesothelioma: Con Argument
Robert B. Cameron (2006)
10.1016/j.rpor.2012.07.015
Radiotherapy applications of patients with malignant mesothelioma: A single center experience.
Muge Akmansu (2012)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
Anne S. Tsao (2009)
10.1016/B978-0-323-24098-7.00046-0
Chapter 46 – Uncommon Thoracic Tumors
Jing Zeng (2016)
10.1016/j.ijrobp.2009.06.037
Radiotherapy in malignant pleural mesothelioma.
Mary Frances McAleer (2009)
10.1002/ijc.25002
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
Kazuyoshi Yanagihara (2010)
10.1007/s00701-002-0945-2
CT-Guided Percutaneous Selective Cordotomy for Treatment of Intractable Pain in Patients with Malignant Pleural Mesothelioma
Yucel Kanpolat (2002)
10.1007/s00595-005-3132-2
Intrapleural Hypotonic Cisplatin Treatment for Malignant Pleural Mesothelioma: In Vitro Experiments and Clinical Application
T. Tagawa (2005)
10.1016/B978-1-4377-1637-5.00044-4
Uncommon Thoracic Tumors
Ramesh Rengan (2011)
10.2147/LCTT.S83338
Modern management of malignant pleural mesothelioma
Shivani Patel (2016)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
10.1007/978-1-61779-797-2_10
Real-time fluorescence imaging of abdominal, pleural, and lymphatic metastases.
Susanne G. Carpenter (2012)
10.1016/j.ijrobp.2011.11.057
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
Pretesh R Patel (2012)
10.1007/s00268-003-7159-5
Radical Surgery for Mesothelioma: How Can We Obtain Evidence?
M. S. Tom Treasure M.D. (2003)
Chapter 8 Mesothelioma : An Evidence-Based Review
Julie Goudreault (2013)
10.4238/2014.January.21.17
Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma.
J. Zhang (2014)
10.1016/B978-0-323-44284-8.00021-1
Malignant and Borderline Mesothelial Tumors of the Pleura
Mark R. Wick (2017)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.4236/HEALTH.2013.56129
Mesothelioma in relation to asbestos exposure in laboratory work
P. Sripaiboonkij (2013)
10.1016/S0761-8425(06)71785-5
4.1. Mésothéliome pleural malin : place de la chirurgie d'exérèse
Roger Giudicelli (2006)
Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma.
Kamal A. Mohammed (2011)
10.1016/S0140-6736(14)60795-9
Surgical resection of mesothelioma: an evidence-free practice
Y C Gary Lee (2014)
10.3816/CLC.2009.n.005
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
A. Tsao (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar